What if your biological age could be reversed — not just slowed down? That’s exactly what scientists at the fictional Novus Institute for Longevity are claiming in a new study that’s generating global attention. Using partial cellular reprogramming, the researchers were able to “reset” aged cells in mice, leading to better physical function, organ regeneration, and a 34% increase in lifespan.

While the term “cellular reprogramming” might sound like science fiction, it’s rooted in Nobel Prize-winning work. The concept involves reverting adult cells to a more youthful, flexible state using a select combination of genes — known as Yamanaka factors — that influence how DNA is expressed. By applying this method intermittently (instead of fully reprogramming cells into stem cells), researchers avoid cancer risks and maintain cellular identity while still rejuvenating tissue.

“This isn’t about immortality — it’s about increasing healthspan,” says Dr. Elise Tanaka, lead author of the study. “Imagine adding more healthy, active years to your life, not just more time.”

In the study, mice received cyclical doses of a reprogramming treatment starting at mid-life. Over the course of 12 months, the treated mice showed better muscle strength, improved cognitive performance, and reduced markers of inflammation and DNA damage compared to controls.

So What’s Next?

Human trials are still years away, but the longevity biotech scene is buzzing. Startups are already racing to bring similar gene therapies and small-molecule alternatives to market.
Investors are pouring billions into this space — and for good reason. The economic value of increasing healthspan by even 10% could rival the impact of curing cancer.

Still, ethical and safety concerns remain. Overstimulation of cell growth could lead to tumor formation, and the long-term consequences of reprogramming therapies in humans are unknown. That’s why the field is now focused on “partial reprogramming” — delivering just enough rejuvenation without resetting too far.

“We’re entering a new era where aging may become something we can manage, not just endure,” says longevity ethicist Marla Chu. “But we need transparency, regulation, and access — or we risk creating a world where only the wealthy get to ‘age backwards’.”

For now, these findings mark a major milestone in our understanding of cellular aging — and a glimpse into what may be possible within our lifetime.